Abivax SA
ABVX105.270USD
+1.370+1.32%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Abivax SA Company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Info
Ticker SymbolABVX
Company nameAbivax SA
IPO dateJun 26, 2015
CEOMr. Marc De Garidel
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address7-11 Boulevard Haussmann
CityPARIS
Stock exchangeEuronext Paris
CountryFrance
Postal code75009
Phone33153830963
Websitehttps://www.abivax.com/
Ticker SymbolABVX
IPO dateJun 26, 2015
CEOMr. Marc De Garidel
Company Executives of Abivax SA
Name
Name/Position
Position
Shareholding
Change
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Nov 8
Updated: Sat, Nov 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
Other
77.69%
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
Other
77.69%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.85%
Investment Advisor
12.52%
Investment Advisor/Hedge Fund
6.12%
Venture Capital
1.86%
Research Firm
0.89%
Other
53.77%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
120
34.39M
46.74%
-4.46M
2025Q2
74
31.84M
43.27%
-317.11K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
TCG Crossover Management, LLC
6.06M
8.23%
--
--
Jun 30, 2025
Deep Track Capital LP
3.48M
4.73%
-99.06K
-2.77%
Jun 30, 2025
Adar1 Capital Management LLC
3.07M
4.17%
+861.32K
+38.97%
Jun 30, 2025
Cormorant Asset Management, LP
2.13M
2.9%
--
--
Jun 30, 2025
Caligan Partners, LP
1.67M
2.28%
+405.28K
+31.93%
Jun 30, 2025
Nantahala Capital Management, LLC
1.48M
2.02%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
1.37M
1.86%
--
--
Jun 30, 2025
VR Adviser, LLC
1.35M
1.83%
--
--
Jun 30, 2025
Great Point Partners, LLC
1.29M
1.76%
-346.49K
-21.15%
Jun 30, 2025
Octagon Capital Advisors LP
1.27M
1.72%
+37.00K
+3.01%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Health Care ETF
4.12%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
Proportion4.12%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0%
Innovator IBD Breakout Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
